Tysabri Accelerated Approval Based On Strength Of Effect, FDA Review Shows
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The degree of Tysabri's treatment effect in multiple sclerosis was integral to FDA's decision to grant the agent accelerated approval, review documents show